Falc Borchard, VP of sales & application at PIA Automation North America discusses how with increasing regulatory expectations and uncertain global supply chains, pharmaceutical manufacturers are rethinking how they design and scale their operations.
Emmet Tilley, quality director at scientific and regulatory consultancy Broughton Group, outlines how creating a quality culture through established practices with new perspectives enables growth while maintaining regulatory integrity.
Markus Junior Maring, product manager, Filtration Consumables, and Marine Cannuel, manager of validation services, examine how specialised validation services can help manufacturers strengthen Annex 1 compliance.
Emmanuel Abate, president genomic medicine and head of sustainability, Cytiva explores how bioprocessing leaders can protect patients, the planet, and their supply chain.
Justin Wilson, partner and life sciences sector specialist at Withers & Rogers, highlights the importance of ensuring IP readiness ahead of an expected surge in M&A activity as the industry approaches the patent cliff.
Megha Sinha, founder and CEO of Kamet Consulting Group explains why the systems most manufacturers use to manage post-approval changes are no longer fit for purpose, and what a viable alternative looks like in the AI age.
Since the introduction of formal GMP regulations in the 60's and 70's, the batch record has been a cornerstone of how pharmaceutical manufacturing operates. David Margetts, group executive director of Factorytalk and BatchLine discusses.
